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patients were treated with geﬁtinib 250 mg/day orally until disease 
progression. The primary endpoint was response rate. The secondary 
endpoints were disease control rate, overall survival, progression-free 
survival, and toxicity.
Results: Thirty-one patients were enrolled in this study from December 
2004 to December 2005. One patient was ineligible because of IIIA 
disease. Of the 30 eligible patients, the median age was 78.5 years, 
16 patients were female, and 14 patients had no smoking history. We 
observed no CR, 7 PR, 8 SD, 13 PD, and 2 NE (unconﬁrmed extra-
murally). The response rate was 23% and the disease control rate was 
50%. The median overall survival was 11.9 months and the median 
progression-free survival was 3.2 months. In never-smokers, the 
response rate was 43%, the disease control rate was 57%, the median 
overall survival was 15.0 months, and the median progression-free 
survival was 7.1 months. The common grade 3 to 4 toxicities were 
rash (7%), diarrhea (3%), anorexia (7%), fatigue (3%), AST (7%), and 
ALT (7%). We encountered one acute myocardial infarction (grade 4) 
that was considered as therapy-unrelated. There was no interstitial lung 
disease and no treatment-related death.
Conclusions: Single-agent geﬁtinib is active and well tolerated in che-
motherapy-naïve elderly patients with lung adenocarcinoma. Geﬁtinib 
may become a new standard treatment characterized by less toxicity, 
especially in never-smokers. Further investigation is warranted in Asia.
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Objective: The objective of this study was to evaluate the technique, 
efﬁcacy, and side effects of percutaneous ethanol injection in patients 
with symptomatic cervical nodal metastases from lung cancer. 
Methods: twenty patients who had received previous chemotherapy 
or radiotherapy for advanced lung cancer presented with symptomatic 
nodal metastases in the neck between May 2006 and october 2006. all 
were unresponsive to chemotherapy and radiotherapy. each metastatic 
lymph node was treated with percutaneous ethanol injection, and pa-
tients received both clinical and sonographic follow-up. 
Results: thirty-ﬁve metastatic lymph nodes in our 20 patients were 
injected. mean sonographic follow-up was 1 months (range, from 0.5 
months to 4 months). Thirty treated lymph nodes(85.7%)decreased in 
mean diameter from 26.2mm before percutaneous ethanol injection to 
15.7mm at 1 month after treatment. the mean improvement in the pain 
score after alcohol injection was 2.5±1.2. nine nodes were re-treated 
1-2months after initial percutaneous ethanol injection because of recov-
ered ﬂow on color Doppler sonography (n = 4), or increased size (n = 
5). No major complications occurred.
Conclusion: Sonographically guided percutaneous ethanol injection 
is a valuable treatment option for patients with symptomatic cervical 
nodal metastases from advanced lung cancer who are not amenable to 
further therapy. 
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Background: Geﬁtinib, an epidermal growth factor receptor(EGFR) 
tyrosine kinase inhibitor, has reported to be effective in refractory non-
small cell lung carcinoma(NSCLC). In a subgroup analysis of ISEL 
trial, oriental and non-smokers had improvements in survival. This 
study aimed to ﬁnd the clinical and genetic parameters that predict the 
response and survival beneﬁt of geﬁtinib in a Korean population.
Methods: Since 2002, 187 patients with NSCLC were treated with 
geﬁtinib and their response evaluations were feasible. The responses 
were recorded as partial remission(PR), stable disease(SD) and 
progression(PD) by RECIST response criteria for solid tumor. Sev-
enty-one tumor DNA were available for the sequence analysis of the 
EGFR gene(exon 18, 19, 20, and 21), 60 tumor DNA were examined 
for K-ras(codon 12, and 61) and 45 for HER-2 gene(exon 19 and 20) 
mutation.
Results: The response rate was signiﬁcantly higher in those who 
never smoked(47.9%) vs. smokers(10.8%, p<0.001), in females(40%) 
vs. males(13.1%, p<0.001), in adenocarcinoma(33%) vs. non-
adenocarcinoma(7.5%, p<0.001) and in EGFR mutants(88.2%) 
vs. wild type(14.8%, p<0.001). By a multivariate logistic regres-
sion analysis, the independent clinical predictors of response were 
adenocarcinoma(OR=0.245, 95% CI, 0.096-0.629, p=0.003) and never 
smokers(OR=0.126, 95% CI, 0.032-0.504, p=0.003). Among patients 
whose EGFR gene sequence was examined, the only independent 
predictor of response was mutation fo EGFR gene(OR=0.038, 95% 
CI, 0.006-0.240, p=0.001). The median survival time from the begin-
ning of treatment with geﬁtinib was 7.7 months(95% CI, 6.25-9.15). 
Median survival was signiﬁcantly longer in responders(29.8 months, 
p<0.001), never smoked patients(26.7 months, p<0.001), females(12.4 
months, p=0.002), adenocarcinoma(9.4 months, p=0.009) and EGFR 
mutants(not reached, p<0.001). The independent clinical predictors of 
the survival were female(OR=2.041, 95% CI, 1.081-3.855, p=0.028) 
and never smokers(OR=0.170, 95% CI, 0.082-0.351, p=0.000). 
In patients whose EGFR gene sequence were analysed, EGFR 
mutation(OR=0.368, 95% CI, 0.145-0.934, p=0.035) and never smok-
ing history(OR=0.177, 95% CI, 0.067-0.465, p=0.000) were indepen-
dent predictors of survival. 
Conclusions: The patients who respondrd to geﬁtinib showed signiﬁ-
cantly longer survival than non-responders. The independent predictors 
of response and survival were never smoking history, adenocarcinoma, 
and female sex. Among patients whose EGFR gene sequence were ana-
lyzed, EGFR gene mutation was the independent predictor of response 
and survival. 
